Patients who are receiving any other investigational agent(s)
Patients who are currently receiving any other investigational agent
Patient is currently receiving or has received another investigational agent within 4 weeks prior to day 1 of study
Patients may not be receiving any other concurrent investigational agents, or have received any investigational agent within four weeks of commencing this protocol.
Patients who are currently receiving another investigational agent are excluded
Patients may not be receiving any other investigational agent
Receiving any other agent which would be considered as a treatment for the lymphoma
Currently receiving any other investigational agent or received an investigational agent within last 30 days of study entry.
Patient is currently receiving or has received another investigational agent within 4 weeks prior to study day 1
Receiving other investigational agent concomitantly
Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
Receiving any other investigational agent that would be considered as a treatment for the lymphoma
Patients who are currently receiving another investigational agent are excluded
Receiving any approved or investigational anti-cancer agent other than those provided for in this study
Participants who are receiving an investigational agent(s)
Patients receiving another investigational agent
Receiving any other investigational agent(s) or has received an investigational agent within the last 30 days
Receiving any other investigational agents, or has received an investigational agent within the last 30 days
Patient is currently receiving or has received another investigational agent within 4 weeks prior to day 1 of study
Patients receiving any other investigational agent (s)
Receiving any other investigational agent
Patients who are currently receiving any other investigational agent
Patients must not be receiving any other investigational agent
Receiving other investigational agent
At least 21 days have passed since receiving any investigational agent at the time of registration
Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
Currently receiving an investigational agent
Receiving or less than 21 days since receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent
PHASE I: Patients who are receiving any other investigational agent
PHASE II: Patients who are receiving any other investigational agent
Receiving any other investigational agent(s) or has received an investigational agent within the last 30 days
Receiving any other investigational agent(s) or has received an investigational agent within the last 30 days
Currently receiving any other investigational agents, or received an investigational agent within 3 weeks of the first dose of nintedanib
Receiving any other investigational agent(s) or has received an investigational agent within the last 30 days
Patients who are receiving any other investigational agent
Receiving any other investigational agent which would be considered as a treatment for the lymphoma
Receiving any other investigational agent
Patient is receiving any other investigational agent
Patients who are receiving any other concurrent investigational agents (patients are eligible to enroll 4 weeks after completion of prior agent)
Patients must not be receiving any other investigational agent
Receiving any other investigational agent
Patients who were currently receiving any other investigational agent.
Patients receiving other investigational agent
Currently receiving another investigational agent
Receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent
Receiving another investigational agent (30 day wash-out required prior to first dose)
Patients that are receiving any other investigational agent
Receiving any investigational agent currently, or within 2 weeks of day 1 of treatment on this study
Patients receiving an investigational agent within 30 days before enrollment
Currently receiving a study therapy or if they had an investigational agent within 4 weeks at the time of enrollment.
Patients must not be receiving any other investigational agent
Patients may not be receiving any other investigational agent with therapeutic anticancer intent
Receiving any other investigational agents or receipt of another investigational agent within 4 weeks of study entry
Patients may not be receiving nor have received any other investigational agent =< 4 weeks prior to study registration
Patients who are receiving any other investigational agent
Patients who are receiving any other investigational agents; if the patient received a previous investigational or other agent or treatment, a washout period of 4 weeks is required
Receiving other investigational agent
Patients receiving other investigational agent
Patients receiving any other current investigational therapeutic agent.
Receiving any other investigational agent
Patients may not be receiving any other investigational agent with therapeutic anticancer intent
The participant is receiving any other investigational agent(s)
Patients receiving any other investigational agent(s)
Patients may not be receiving any other investigational agent
Receiving any other investigational agent
Receiving any approved or investigational anti-cancer agent other than those provided for in this study
Receiving erythropoietin stimulating agent
Receiving any agent classified as an antioxidant
Patient who is receiving investigational agent(s) as part of another clinical study at the time of screening or who anticipates receiving investigational agent(s) during their scheduled radiotherapy and concomitant daily temozolomide therapy (e.g. through the BMX001, MRZ 112, and BMX 209-548 studies)
Patient must not be receiving any other anti-cancer agent
The participant is receiving any other investigational agent(s).
The participant is receiving any other investigational agent(s).
